WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328409
CAS#: 129273-38-7 (HCl)
Description: Perospirone HCl Dihydrate, also known as SM-9018 and Lullan, is an atypical antipsychotic agent for the treatment of schizophrenia. Its primary mode of action is through antagonism of serotonin 5-HT2A and dopamine D2 receptors.
Hodoodo Cat#: H328409
Name: Perospirone HCl
CAS#: 129273-38-7 (HCl)
Chemical Formula: C23H31ClN4O2S
Exact Mass: 0.00
Molecular Weight: 463.037
Elemental Analysis: C, 59.66; H, 6.75; Cl, 7.66; N, 12.10; O, 6.91; S, 6.92
Related CAS #: 192052-81-6 (HCl dihydrate) 150915-41-6 (free base) 129273-38-7 (HCl),
Synonym: Perospirone HCl Dihydrate; SM-9018; SM9018; SM 9018; Lullan
IUPAC/Chemical Name: (3aR,7aS)-2-(4-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)butyl)hexahydro-1H-isoindole-1,3(2H)-dione hydrochloride
InChi Key: HIZFAPMOZFYELI-GNXQHMNLSA-N
InChi Code: InChI=1S/C23H30N4O2S.ClH/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21;/h3-4,9-10,17-18H,1-2,5-8,11-16H2;1H/t17-,18+;
SMILES Code: O=C1N(CCCCN2CCN(C3=NSC4=C3C=CC=C4)CC2)C([C@]5([H])CCCC[C@]15[H])=O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 150915-41-6(Perospirone ) 192052-81-6(Perospirone HCl Dihydrate)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 463.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Kishi T, Iwata N. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. Review. PubMed PMID: 23812802.
2: Kishi T, Matsuda Y, Iwata N. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014 Feb 4;9(2):e88049. doi: 10.1371/journal.pone.0088049. eCollection 2014. PubMed PMID: 24505373; PubMed Central PMCID: PMC3913743.
3: Yomiya K, Takei D, Kurosawa H, Kono B. [A study on the antiemetic effect and extrapyramidal symptoms of prochlorperazine versus perospirone for the control of nausea and vomiting due to opioid introduction]. Gan To Kagaku Ryoho. 2013 Aug;40(8):1037-41. Japanese. PubMed PMID: 23986047.
4: Tagami K, Mawatari H, Abe K, Takeno N, Syuuto C, Saito O, Akagi T, Matoba M. Perospirone Exhibits Antiemetic Efficacy against Opioid-Induced Nausea in Patients with Advanced Cancer. J Palliat Med. 2015 Oct;18(10):823-4. doi: 10.1089/jpm.2015.0219. Epub 2015 Aug 24. PubMed PMID: 26302110.
5: Tsujino N, Nemoto T, Morita K, Katagiri N, Ito S, Mizuno M. Long-term Efficacy and Tolerability of Perospirone for Young Help-seeking People at Clinical High Risk: a Preliminary Open Trial. Clin Psychopharmacol Neurosci. 2013 Dec;11(3):132-6. doi: 10.9758/cpn.2013.11.3.132. Epub 2013 Dec 24. PubMed PMID: 24465249; PubMed Central PMCID: PMC3897761.
6: Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:110-4. doi: 10.1016/j.pnpbp.2012.09.010. Epub 2012 Sep 27. PubMed PMID: 23022672.
7: Chen J, Zhi S. A case of neuroleptic malignant syndrome induced by perospirone. Shanghai Arch Psychiatry. 2013 Dec;25(6):387-9. doi: 10.3969/j.issn.1002-0829.2013.06.008. PubMed PMID: 24991182; PubMed Central PMCID: PMC4054582.
8: Higuchi Y, Sumiyoshi T, Ito T, Suzuki M. Perospirone normalized P300 and cognitive function in a case of early psychosis. J Clin Psychopharmacol. 2013 Apr;33(2):263-6. doi: 10.1097/JCP.0b013e318287c527. PubMed PMID: 23422402.
9: Takahashi S, Suzuki M, Uchiyama M. A case of schizophrenia with meige syndrome induced by perospirone successfully treated with biperiden. J Neuropsychiatry Clin Neurosci. 2013 Winter;25(1):E28. doi: 10.1176/appi.neuropsych.12020029. PubMed PMID: 23487218.
10: Suzuki Y, Watanabe J, Sugai T, Fukui N, Ono S, Tsuneyama N, Saito M, Someya T. Improvement in QTc prolongation induced by zotepine following a switch to perospirone. Psychiatry Clin Neurosci. 2012 Apr;66(3):244. doi: 10.1111/j.1440-1819.2012.02321.x. PubMed PMID: 22443250.
